Hematology TimesPathogenesis of breast-implant-associated ALCLMarch 7, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesStudy sheds light on genetic landscape of HSTLMarch 6, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesPotential therapeutic strategy for BL, DLBCLMarch 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesDrug granted orphan status for follicular lymphomaFebruary 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFactors linked to B-NHL in Palestinians, IsraelisFebruary 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesEuropean Commission approves rituximab biosimilarFebruary 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesImmunotherapy receives fast track designationFebruary 22, 2017Lymphoma & Plasma Cell DisordersTransplantationHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesProximity to oil, gas wells linked to ALLFebruary 16, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLNon-Hodgkin Lymphoma
Hematology TimesDrug produces high response rates in AITLFebruary 16, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesInvestigators report new risk loci for CLLFebruary 9, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesObinutuzumab approved to treat FL in CanadaFebruary 8, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesNCCN releases patient guidelines for WM/LPLFebruary 7, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesOS is worse with refractory vs relapsed PTCLFebruary 3, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesTherapy granted PIM designation for CTCLFebruary 3, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesRegimens seem similarly effective in ENKTLFebruary 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
